article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Food and Drug Administration (FDA). Trends in Non-Human Primate Use for Research and Testing.

article thumbnail

Organon drug for endometriosis falls short in mid-stage study

BioPharma Drive: Drug Pricing

The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029. Organon acquired the drug in its purchase of Forendo Pharma in 2021. Recommended Reading Endometriosis drug research, long underfunded, confronts familiar problems in women’s health By Delilah Alvarado • Dec.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Drive: Drug Pricing

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

article thumbnail

Preclinical vs. Clinical Biomarkers: Understanding Their Distinct Roles in Drug Development

Crown Bioscience

The Importance of Biomarkers in Drug Development Biomarkers have become essential tools in modern drug discovery and development, enabling researchers to predict drug efficacy, monitor disease progression, and tailor treatments to specific patient populations.

article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

Continue reading to learn more about IMIDs and some of the challenges facing the field, and to review some in vivo preclinical models that can be used to guide IMID drug research and development.

article thumbnail

eBook: Unlocking Undruggable Targets

DrugBank

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets.

article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.